{
    "nct_id": "NCT05803941",
    "official_title": "A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer",
    "inclusion_criteria": "* Signed informed consent must be obtained prior to participation in the study\n* Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "- Inability to complete the needed investigational examinations due to any reason.",
    "miscellaneous_criteria": ""
}